Editas Medicine, Inc.
NASDAQ:EDIT · NASDAQ Global Select
+$0.07 today
Vol 3.28M · Avg 2.06M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+28.10%
Period High
$4.15
Period Low
$1.67
Latest
$2.69
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.31B
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$488.98M
Cabaletta Bio, Inc.
NASDAQ:CABA
$469.19M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$348.58M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$348.49M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$347.32M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$293.05M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$223.56M
ProQR Therapeutics N.V.
NASDAQ:PRQR
$195.44M
Immutep Limited
NASDAQ:IMMP
$55.44M
What is the latest EDIT filing?
The latest filing shown is 4 dated Jun 5, 2026.
How many recent filings does EDIT have?
Intrinsic Alpha currently shows 20 recent filings for EDIT.
Explore More
Continue the stock analysis
Jump to another research area for this company.